Patients treated with an antibody for acute cellular rejection were 23 times more likely to experience an immediate reaction of fever, chills and malaise than those receiving steroid, and muromonab‐CD3 treated patients were three times more likely to experience this reaction than those treated with other antibodies for the treatment of first ....